Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403

被引：6

作者：

Goldberg, S. ^{[1
]}

Redman, M. ^{[2
]}

Lilenbaum, R. ^{[1
]}

Politi, K. ^{[1
]}

Stinchcombe, T. ^{[3
]}

Horn, L. ^{[4
]}

Chen, E. ^{[5
]}

Mashru, S. ^{[6
]}

Gettinger, S. ^{[1
]}

Melnick, M. A. ^{[7
]}

Miao, J. ^{[2
]}

Moon, J. ^{[2
]}

Kelly, K. ^{[8
]}

Gandaram, D. ^{[9
]}

机构：

[1] Yale Univ, Sch Med, New Haven, CT USA

[2] Fred Hutchinson Canc Res Ctr, Swog Stat Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[3] Duke Univ, Durham, NC USA

[4] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[5] Kaiser Permanente, Bellflower, CA USA

[6] Kaiser Permanente, Portland, OR USA

[7] Yale Sch Med, New Haven, CT USA

[8] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA

[9] Univ Calif Davis, Ctr Comprehens Canc, Div Hem Oncol, Sacramento, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

NSCLC; EGFR;

D O I：

10.1016/j.jtho.2018.08.290

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA10.04

引用

页码：S343 / S344

页数：2

共 50 条

[21] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
Blaquier, Juan Bautista
Ortiz-Cuaran, Sandra
Ricciuti, Biagio
Mezquita, Laura
Cardona, Andres Felipe
Recondo, Gonzalo
CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
[22] Patritumab Deruxtecan Is Efficacious in EGFR-Mutant Non-Small Cell Lung Cancer
Zhang, H.
Yu, X.
Ye, J.
Li, H.
Hu, J.
Tan, Y.
CANCER DISCOVERY, 2023, 13 (12) : 2501 - 2501
[23] The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer
Boussageon, Maxime
Swalduz, Aurelie
Perol, Maurice
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (10) : 1071 - 1080
[24] Intracranial Efficacy of Afatinib as First-line Treatment in Common/Uncommon EGFR-Mutant Advanced Non-small Cell Lung Cancer Patients
Liang, Y.
Kang, L.
Lin, Y.
Mai, J.
Zou, Q.
Huang, C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S345 - S346
[25] Osimertinib in EGFR-mutant non-small cell lung carcinoma
Lorenz, Judith
PNEUMOLOGIE, 2023, 77 (11): : 847 - 847
[26] Efficacy and Outcomes of Immunotherapy-Based Treatments in EGFR-Mutant Non-Small Cell Lung Cancer
Chen, I. -T.
Huang, H. -C.
Chiang, C. -L.
Shen, C. -I.
Tseng, Y. -H.
Chen, Y. -M.
Luo, Y. -H.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S604 - S604
[27] INDIRECT COMPARISON OF EFFICACY AND SAFETY FOR AUMOLERTINIB VS OSIMERTINIB IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
Stergiopoulos, S.
King, S.
Curtis, M.
Dillon, S. A.
Akehurst, R.
Lee, D.
Guelfucci, F.
Ngami, A.
Bianic, F.
Li, Y.
Ma, X.
Ali, S.
Miller, V. A.
Popat, S.
VALUE IN HEALTH, 2022, 25 (12) : S42 - S42
[28] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
Kyoko Otsuka
Akito Hata
Jumpei Takeshita
Chiyuki Okuda
Reiko Kaji
Katsuhiro Masago
Shiro Fujita
Nobuyuki Katakami
Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
[29] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
Otsuka, Kyoko
Hata, Akito
Takeshita, Jumpei
Okuda, Chiyuki
Kaji, Reiko
Masago, Katsuhiro
Fujita, Shiro
Katakami, Nobuyuki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
[30] ACTIVITY OF AFATINIB/CETUXIMAB IN PATIENTS (PTS) WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AND ACQUIRED RESISTANCE (AR) TO EGFR INHIBITORS
Janjigian, Y. Y.
Smit, E. F.
Horn, L.
Groen, H. J. M.
Camidge, D. R.
Gettinger, S.
Fu, Y.
Denis, L. J.
Miller, V.
Pao, W.
ANNALS OF ONCOLOGY, 2012, 23 : 401 - 401

← 1 2 3 4 5 →